Getein Biotech, Inc
SHH: 603387.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Enben Su
- Employees
- 1,947
- Headquarters
- Nanjing, China
- IPO year
- 2017
- Market cap
- CN¥5.0B
- Website
- https://www.bio-gp.com.cn
Loading 603387…
Loading profile data…Frequently asked questions about 603387
What does Getein Biotech, Inc (603387.SS) do?
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, c...
Where does 603387.SS trade?
Getein Biotech, Inc (603387.SS) trades on the Shanghai Stock Exchange.
What sector is 603387.SS in?
Getein Biotech, Inc (603387.SS) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Getein Biotech, Inc?
Enben Su is the chief executive officer of Getein Biotech, Inc (603387.SS).
Where is Getein Biotech, Inc headquartered?
Getein Biotech, Inc is headquartered in China.
Does 603387.SS pay a dividend?
Yes — Getein Biotech, Inc (603387.SS) paid a trailing twelve-month dividend of CNY 0.18 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603387.SS go public?
Getein Biotech, Inc (603387.SS) completed its initial public offering in 2017.